A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies
Introduction: As Parkinson's disease (PD) progresses, the number/frequency of PD medications tend to increase, which is correlated with decreased patient compliance and suboptimal control of PD symptoms. We investigated efficacy and safety of levodopa-carbidopa intestinal gel (LCIG) daytime mon...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-01-01
|
| Series: | Clinical Parkinsonism & Related Disorders |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590112519300325 |
| _version_ | 1818955163554021376 |
|---|---|
| author | James T. Boyd Cindy Zadikoff Janet A. Benesh Jorge Zamudio Weining Z. Robieson Pavnit Kukreja Masayuki Yokoyama Mustafa S. Siddiqui |
| author_facet | James T. Boyd Cindy Zadikoff Janet A. Benesh Jorge Zamudio Weining Z. Robieson Pavnit Kukreja Masayuki Yokoyama Mustafa S. Siddiqui |
| author_sort | James T. Boyd |
| collection | DOAJ |
| description | Introduction: As Parkinson's disease (PD) progresses, the number/frequency of PD medications tend to increase, which is correlated with decreased patient compliance and suboptimal control of PD symptoms. We investigated efficacy and safety of levodopa-carbidopa intestinal gel (LCIG) daytime monotherapy (with or without nighttime oral levodopa-carbidopa) compared with polytherapy (LCIG with ≥1 adjunctive PD therapy) in advanced PD patients. Methods: This post hoc descriptive study compared LCIG stable daytime monotherapy with LCIG stable polytherapy in all six phase 3/3b open-label studies from both US and international sites; because of study design variability, pooling data for comparison was not appropriate. Efficacy assessments included PD diary data (mean change from baseline in “Off” time and “On” time with or without troublesome dyskinesia), mean Unified PD Rating Scale scores (Parts II and III), and 39-item Parkinson's Disease Questionnaire (PDQ-39) summary index. Adverse events were also assessed. Results: Overall, LCIG daytime monotherapy and polytherapy demonstrated similar efficacy/safety profiles in advanced PD patients, regardless of treatment duration or population. LCIG monotherapy vs. polytherapy groups experienced similar mean decreases in “Off” time (4.6 vs. 4.1 h/day) and similar increases in “On” time without troublesome dyskinesia (4.6 vs. 4.1 h/day). In most studies, PDQ-39 summary index scores were reduced from baseline by ≥5 points, regardless of patient population or study duration. Adverse events not related to the procedure/device were similar in both groups. Conclusion: Our data suggest that, for appropriate patients, LCIG monotherapy can provide a more simplified treatment option with similar efficacy and safety. |
| first_indexed | 2024-12-20T10:33:42Z |
| format | Article |
| id | doaj.art-0aaba9c46e2842f084599e752bb59234 |
| institution | Directory Open Access Journal |
| issn | 2590-1125 |
| language | English |
| last_indexed | 2024-12-20T10:33:42Z |
| publishDate | 2020-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Parkinsonism & Related Disorders |
| spelling | doaj.art-0aaba9c46e2842f084599e752bb592342022-12-21T19:43:40ZengElsevierClinical Parkinsonism & Related Disorders2590-11252020-01-0122534A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studiesJames T. Boyd0Cindy Zadikoff1Janet A. Benesh2Jorge Zamudio3Weining Z. Robieson4Pavnit Kukreja5Masayuki Yokoyama6Mustafa S. Siddiqui7Department of Neurological Sciences, University of Vermont Larner College of Medicine, 1 South Prospect Street, UHC – Arnold 2, Burlington, VT 05401, USA; Corresponding author at: Department of Neurological Sciences, University of Vermont, Larner College of Medicine, 1 South Prospect Street, UHC – Arnold 2, Burlington, VT 05401, USA.AbbVie, Inc., 1 Waukegan Rd, North Chicago, IL 60064, USAAbbVie, Inc., 1 Waukegan Rd, North Chicago, IL 60064, USAAbbVie, Inc., 1 Waukegan Rd, North Chicago, IL 60064, USAAbbVie, Inc., 1 Waukegan Rd, North Chicago, IL 60064, USAAbbVie, Inc., 1 Waukegan Rd, North Chicago, IL 60064, USAAbbVie, Inc., 3-1-21 Shibaura, Minato-ku, Tokyo 108-6302, JapanDepartment of Neurology, Wake Forest School of Medicine, 475 Vine Street, Winston-Salem, NC 27101, USAIntroduction: As Parkinson's disease (PD) progresses, the number/frequency of PD medications tend to increase, which is correlated with decreased patient compliance and suboptimal control of PD symptoms. We investigated efficacy and safety of levodopa-carbidopa intestinal gel (LCIG) daytime monotherapy (with or without nighttime oral levodopa-carbidopa) compared with polytherapy (LCIG with ≥1 adjunctive PD therapy) in advanced PD patients. Methods: This post hoc descriptive study compared LCIG stable daytime monotherapy with LCIG stable polytherapy in all six phase 3/3b open-label studies from both US and international sites; because of study design variability, pooling data for comparison was not appropriate. Efficacy assessments included PD diary data (mean change from baseline in “Off” time and “On” time with or without troublesome dyskinesia), mean Unified PD Rating Scale scores (Parts II and III), and 39-item Parkinson's Disease Questionnaire (PDQ-39) summary index. Adverse events were also assessed. Results: Overall, LCIG daytime monotherapy and polytherapy demonstrated similar efficacy/safety profiles in advanced PD patients, regardless of treatment duration or population. LCIG monotherapy vs. polytherapy groups experienced similar mean decreases in “Off” time (4.6 vs. 4.1 h/day) and similar increases in “On” time without troublesome dyskinesia (4.6 vs. 4.1 h/day). In most studies, PDQ-39 summary index scores were reduced from baseline by ≥5 points, regardless of patient population or study duration. Adverse events not related to the procedure/device were similar in both groups. Conclusion: Our data suggest that, for appropriate patients, LCIG monotherapy can provide a more simplified treatment option with similar efficacy and safety.http://www.sciencedirect.com/science/article/pii/S2590112519300325LCIGLevodopaMonotherapyParkinson's disease |
| spellingShingle | James T. Boyd Cindy Zadikoff Janet A. Benesh Jorge Zamudio Weining Z. Robieson Pavnit Kukreja Masayuki Yokoyama Mustafa S. Siddiqui A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies Clinical Parkinsonism & Related Disorders LCIG Levodopa Monotherapy Parkinson's disease |
| title | A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies |
| title_full | A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies |
| title_fullStr | A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies |
| title_full_unstemmed | A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies |
| title_short | A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies |
| title_sort | post hoc comparison of levodopa carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced parkinson s disease results from 6 phase 3 3b open label studies |
| topic | LCIG Levodopa Monotherapy Parkinson's disease |
| url | http://www.sciencedirect.com/science/article/pii/S2590112519300325 |
| work_keys_str_mv | AT jamestboyd aposthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT cindyzadikoff aposthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT janetabenesh aposthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT jorgezamudio aposthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT weiningzrobieson aposthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT pavnitkukreja aposthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT masayukiyokoyama aposthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT mustafassiddiqui aposthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT jamestboyd posthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT cindyzadikoff posthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT janetabenesh posthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT jorgezamudio posthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT weiningzrobieson posthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT pavnitkukreja posthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT masayukiyokoyama posthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies AT mustafassiddiqui posthoccomparisonoflevodopacarbidopaintestinalgeldaytimemonotherapyvspolytherapysafetyandefficacyinpatientswithadvancedparkinsonsdiseaseresultsfrom6phase33bopenlabelstudies |